retatrutide clinical trial stage for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational trials - Giblin - 2026 - Diabetes, Obesity and Metabolism retatrutide parkinson's clinical trial Reta

Conclusion Dietary modification personalized to individual preferences and treatment goals (e.g., caloric deficits of 500 kcal/day), combined with structured physical activity (e.g., 150 minutes of moderate-to-vigorous exercise per week), produces additive benefits beyond GLP-1 therapy alone, enhancing weight loss, improving body composition, and reducing visceral fat and inflammation

Going from 68 weeks to 104 weeks added only 0.3 percentage points of additional weight loss

Both represent breakthrough advances in weight management

Watch & Learn See What Our Patients Experience Frequently Asked Questions Both are GLP-1 receptor agonist medications used for weight loss

Journal of Diabetes 10353356